- Email: [email protected]
5093252 Transcription terminator and related recombinant DNA vectors and transformants
PATENT ABSMUXTS
286
so93245 LABELING BY SIMULTANEOUS LIGATION AND RESTRICTION Douglas H Keith, McBride, Norman Applied Biosystems
Mel Kronick, Lincoln J M Whiteley assigned to
Termini of restricted double-stranded DNA fragments are modified by ligating the fragments with terminal phosphate-free double-stranded oligonucleotides having a complementary terminus in the presence of a restriction enzyme and a ligase, where joining of the complementary ends results in loss of the restriction enzyme recognition sequence.
5093246 RNA RIBOZYME POLYMERASES, DEPHOSPHORYLASES, RESTRICTION ENDORIBONUCLEASES AND METHODS Thomas Cech, Arthur Zaug, Michael D Been assigned to University Patents Inc RNA enzymes or ribozymes can act as endoribonucleases, catalyzing the cleavage of RNA molecules with a sequence specificity of cleavage greater than that of known ribonucleases and approaching that of the DNA restriction endonucleases, thus serving as RNA sequence specific endoribonucleases. An example is a shortened form of the self-splicing ribonsomal RNA intervening sequence of Tetrahymena (L-19 IVS RNA). Site-specific mutagenesis of the enzyme active site of the L-19 IVS RNA alters the substrate sequence specificity in a predictable manner, allowing a set of sequence-specific endoribonucleases to be synthesized. Varying conditions allow the ribozyme to act as a polya merase (nucleotidyltransferase), dephosphorylase (acid phosphatase or phosphotransferase) or a sequence-specific endoribonuclease.
5993251 CASSETTE
METHOD OF GENE SYNTHESIS
John H Richards, Sheila A Iverson, Dianne Perez assigned to California Institute of Technology The method of synthesizing
a segment of DNA,
typically a gene, of predetermined strubrure which comprises synthesizing a first pair of oligonucleotides having ends complementary to the ends enzymatically made at a restriction site on a standard plasmid vector, said first pair of oligonucleotides including adjacent their ends portions of said predetermined structure and each having a pair of restriction sites internal to said portions of predetermined structure which restriction sites are unique to the enzyme and not present in the plasmid vector, cloning said first pair of oligonucleotides into said standard plasmid vector, and amplifying said plasmid vector in vivo to recover plasmid vector containing said first pair of oligonucleotides, repeating said method with a second pair of ologonucleotides, containing portions of predetermined structure which are adjacent to the portions present in the first pair of oligonucleotides, and continuing said repetition until all of said segment of predetermined structure has been cloned into said standard vector and amplified.
5993252 TRANSCRIPTION TERMINATOR AND RELATED RECOMBINANT DNA VECTORS AND TRANSFORMANTS Stuart A Kuhstoss, R Nagaraja Eli Lilly and Company
Rao assigned to
A transcription terminator is disclosed comprising a DNA sequence capable of functioning as a transcription terminator in a microorganism of the order Actinomycetales. These transcription terminators are functional in both grampositive and gram-negative microorganisms, especially Streptomyces ambofaciens. Additionally, a series of recombinant DNA cloning vectors suitable for isolating the disclosed transcription terminators are set forth.
5093257 HYBRID PROKARYOTIC POLYPEPTIDES PRODUCED IN VIVO HOMOLOGOUS RECOMBINATION Gregory L Gray assigned to Genencor tional Inc
BY
Interna-
Novel circular vectors containing a recplicable DNA sequence and DNA sequences encoding all
287
PATENTAB!STRACTS
or part of at least two distinct parental polypeptides are disclosed. Such vectors are used in novel processes utilizing in viva recombination to produce recombined circular vectors containing said replicable DNA sequences and hybrid DNA sequences comprising: (1) a first DNA sequence encoding the amino-terminal portion of a hybrid polypeptide corresponding to a first part of a first parental polypeptide sequence and (2) a second DNA sequence encoding a carboxy-terminal portion of said hybrid polypeptide corresponding to a first part of a second parental polypeptide sequence. The hybrid DNA sequences of such recombined circular vectors can exprress novel hybrid polypeptides such as hybrid enzymes in general and in particular hybrid amylases and proteases. Various other processes are disclosed to isolate the recombined circular vector containing said hybrid DNA sequences.
SO93258 RECOMBINANT FOWLPOX VIRUS AND RECOMBINATION VECTOR Lawrence Cohen, Dennis L Panicali assigned to Therion Biologics Corporation Recombinant fowlpox virus (FPV) capable of expressing immunogenic proteins of fowl pathogens are described. The FPV express DNA of the pathogen under the direction of FPV promoters. The recombinant FPV provide live vaccines for poultry and other animals.
5993261 CANCER-RELATED ANTIGENSPECIFIC HUMAN IMMUNOGLOBULINS AND HUMAN/HUMAN HYBRIDOMAS HAVING THE ABILITY TO PRODUCE SAID HUMAN IMMUNOGLOBULINS Hideaki Hagiwara, Junzo Nagao, Kasai shi, Hyogo ken, Japan assigned to Hagiwara Yoshihid; Hagiwara Hideaki A new human/human fused cell clone derived from human B cells having the ability to produce immunoglobulins and human B cells substantially lacking the ability to produce immunohuman antigen-specific globulins, the produced by immunoglobulins human/human fused cell clone, and a method of producing the human immunoglobulins. More
specifically, a human/human hybridoma having the ability to produce antigen-specific human immunoglobulins, which is a human/human fused cell strain derived from human B cells of a human patient with liver cancer and a subclone of a human lymphoblast cell strain; and antigenspecific human immunoglobulins produced by the human/human fused cell strain.
5094945 INHIBITION RESISTANT 5ENOLPYRUVYL 3PHOSPHOSHIKIMATE SYNTHASE, PRODUCTION AND USE Luca Comai assigned to Calgene Inc Enhanced resistance to glyphosate, an inhibitor of the aromatic amino acid biosynthesis pathway, is imparted to a glyphosate sensitive host. A mutated aroA gene is employed which expresses 5-enolpyruvyl 3-phosphoshikimate synthase (EC: 2.5.1.19) (ES-3-P synthase). Methods are provided for obtaining the aroA mutation which provides the enzyme resistant to inhibition by glyphosate, means for introducing the structural gene into a sensitive host, as well as providing a method of producing the enzyme. The E. coli strain C600 (pPMG1) has been deposited at the A.T.C.C. on December 14, 1982 and given A.T.C.C. Accession No. 39256.
5095096 FUSED PROTEIN COMPRISING LYMPHOTOXIN Tetsuzo Miki, Seishi Kato, Hiroshi Osada, Abiko, Japan assigned to Sagami Chemical Research Center; Central Glass Company Ltd ]Hodogaya Chemical Co Ltd INippon Soda Company Ltd INissan Chemical Industries Ltd ]Tosoh Corporati A fused protein comprising a polypetide containing an antibody binding site of protein A and a polypeptide of lymphotoxin, and having biological activities of lymphotoxin and an ability to bind to an antibody is disclosed. Further, a process for the production of the fused protein, as well as a DNA coding for the fused protein, a plasmid containing the DNA, and E. coli transformed with the plasmid, necessary for the above-mentioned process, are provided.
286
so93245 LABELING BY SIMULTANEOUS LIGATION AND RESTRICTION Douglas H Keith, McBride, Norman Applied Biosystems
Mel Kronick, Lincoln J M Whiteley assigned to
Termini of restricted double-stranded DNA fragments are modified by ligating the fragments with terminal phosphate-free double-stranded oligonucleotides having a complementary terminus in the presence of a restriction enzyme and a ligase, where joining of the complementary ends results in loss of the restriction enzyme recognition sequence.
5093246 RNA RIBOZYME POLYMERASES, DEPHOSPHORYLASES, RESTRICTION ENDORIBONUCLEASES AND METHODS Thomas Cech, Arthur Zaug, Michael D Been assigned to University Patents Inc RNA enzymes or ribozymes can act as endoribonucleases, catalyzing the cleavage of RNA molecules with a sequence specificity of cleavage greater than that of known ribonucleases and approaching that of the DNA restriction endonucleases, thus serving as RNA sequence specific endoribonucleases. An example is a shortened form of the self-splicing ribonsomal RNA intervening sequence of Tetrahymena (L-19 IVS RNA). Site-specific mutagenesis of the enzyme active site of the L-19 IVS RNA alters the substrate sequence specificity in a predictable manner, allowing a set of sequence-specific endoribonucleases to be synthesized. Varying conditions allow the ribozyme to act as a polya merase (nucleotidyltransferase), dephosphorylase (acid phosphatase or phosphotransferase) or a sequence-specific endoribonuclease.
5993251 CASSETTE
METHOD OF GENE SYNTHESIS
John H Richards, Sheila A Iverson, Dianne Perez assigned to California Institute of Technology The method of synthesizing
a segment of DNA,
typically a gene, of predetermined strubrure which comprises synthesizing a first pair of oligonucleotides having ends complementary to the ends enzymatically made at a restriction site on a standard plasmid vector, said first pair of oligonucleotides including adjacent their ends portions of said predetermined structure and each having a pair of restriction sites internal to said portions of predetermined structure which restriction sites are unique to the enzyme and not present in the plasmid vector, cloning said first pair of oligonucleotides into said standard plasmid vector, and amplifying said plasmid vector in vivo to recover plasmid vector containing said first pair of oligonucleotides, repeating said method with a second pair of ologonucleotides, containing portions of predetermined structure which are adjacent to the portions present in the first pair of oligonucleotides, and continuing said repetition until all of said segment of predetermined structure has been cloned into said standard vector and amplified.
5993252 TRANSCRIPTION TERMINATOR AND RELATED RECOMBINANT DNA VECTORS AND TRANSFORMANTS Stuart A Kuhstoss, R Nagaraja Eli Lilly and Company
Rao assigned to
A transcription terminator is disclosed comprising a DNA sequence capable of functioning as a transcription terminator in a microorganism of the order Actinomycetales. These transcription terminators are functional in both grampositive and gram-negative microorganisms, especially Streptomyces ambofaciens. Additionally, a series of recombinant DNA cloning vectors suitable for isolating the disclosed transcription terminators are set forth.
5093257 HYBRID PROKARYOTIC POLYPEPTIDES PRODUCED IN VIVO HOMOLOGOUS RECOMBINATION Gregory L Gray assigned to Genencor tional Inc
BY
Interna-
Novel circular vectors containing a recplicable DNA sequence and DNA sequences encoding all
287
PATENTAB!STRACTS
or part of at least two distinct parental polypeptides are disclosed. Such vectors are used in novel processes utilizing in viva recombination to produce recombined circular vectors containing said replicable DNA sequences and hybrid DNA sequences comprising: (1) a first DNA sequence encoding the amino-terminal portion of a hybrid polypeptide corresponding to a first part of a first parental polypeptide sequence and (2) a second DNA sequence encoding a carboxy-terminal portion of said hybrid polypeptide corresponding to a first part of a second parental polypeptide sequence. The hybrid DNA sequences of such recombined circular vectors can exprress novel hybrid polypeptides such as hybrid enzymes in general and in particular hybrid amylases and proteases. Various other processes are disclosed to isolate the recombined circular vector containing said hybrid DNA sequences.
SO93258 RECOMBINANT FOWLPOX VIRUS AND RECOMBINATION VECTOR Lawrence Cohen, Dennis L Panicali assigned to Therion Biologics Corporation Recombinant fowlpox virus (FPV) capable of expressing immunogenic proteins of fowl pathogens are described. The FPV express DNA of the pathogen under the direction of FPV promoters. The recombinant FPV provide live vaccines for poultry and other animals.
5993261 CANCER-RELATED ANTIGENSPECIFIC HUMAN IMMUNOGLOBULINS AND HUMAN/HUMAN HYBRIDOMAS HAVING THE ABILITY TO PRODUCE SAID HUMAN IMMUNOGLOBULINS Hideaki Hagiwara, Junzo Nagao, Kasai shi, Hyogo ken, Japan assigned to Hagiwara Yoshihid; Hagiwara Hideaki A new human/human fused cell clone derived from human B cells having the ability to produce immunoglobulins and human B cells substantially lacking the ability to produce immunohuman antigen-specific globulins, the produced by immunoglobulins human/human fused cell clone, and a method of producing the human immunoglobulins. More
specifically, a human/human hybridoma having the ability to produce antigen-specific human immunoglobulins, which is a human/human fused cell strain derived from human B cells of a human patient with liver cancer and a subclone of a human lymphoblast cell strain; and antigenspecific human immunoglobulins produced by the human/human fused cell strain.
5094945 INHIBITION RESISTANT 5ENOLPYRUVYL 3PHOSPHOSHIKIMATE SYNTHASE, PRODUCTION AND USE Luca Comai assigned to Calgene Inc Enhanced resistance to glyphosate, an inhibitor of the aromatic amino acid biosynthesis pathway, is imparted to a glyphosate sensitive host. A mutated aroA gene is employed which expresses 5-enolpyruvyl 3-phosphoshikimate synthase (EC: 2.5.1.19) (ES-3-P synthase). Methods are provided for obtaining the aroA mutation which provides the enzyme resistant to inhibition by glyphosate, means for introducing the structural gene into a sensitive host, as well as providing a method of producing the enzyme. The E. coli strain C600 (pPMG1) has been deposited at the A.T.C.C. on December 14, 1982 and given A.T.C.C. Accession No. 39256.
5095096 FUSED PROTEIN COMPRISING LYMPHOTOXIN Tetsuzo Miki, Seishi Kato, Hiroshi Osada, Abiko, Japan assigned to Sagami Chemical Research Center; Central Glass Company Ltd ]Hodogaya Chemical Co Ltd INippon Soda Company Ltd INissan Chemical Industries Ltd ]Tosoh Corporati A fused protein comprising a polypetide containing an antibody binding site of protein A and a polypeptide of lymphotoxin, and having biological activities of lymphotoxin and an ability to bind to an antibody is disclosed. Further, a process for the production of the fused protein, as well as a DNA coding for the fused protein, a plasmid containing the DNA, and E. coli transformed with the plasmid, necessary for the above-mentioned process, are provided.